Conference Coverage
Conference Coverage
Single-cell genomics drive progress toward human breast cell atlas development
SAN ANTONIO – Improved understanding of the cellular landscape of both normal breast tissue and breast cancer could...
Conference Coverage
GALLIUM: MRD response correlates with outcomes in follicular lymphoma
SAN DIEGO – MRD response at the end of induction correlates with outcomes in previously untreated follicular lymphoma patients receiving...
Conference Coverage
Applying ECHELON-2 results to clinical practice
LA JOLLA, CALIF. – At the annual T-cell Lymphoma Forum, physicians discussed how the ECHELON-2 trial may affect clinical practice.
Conference Coverage
Thrombin generation looks promising as a hemophilia biomarker
SAN DIEGO – Thrombin generation appears better able to differentiate between bleeding severities, compared with baseline factor activity.
Conference Coverage
Gastrectomy does not alter benefit of new oral chemo in gastric cancer
SAN FRANCISCO – In the phase 3 TAGS trial, the gastrectomy subgroup did have higher rates of grade 3 or 4 adverse events.
Conference Coverage
Study identifies four patient subgroups in hemophilia A
SAN DIEGO – The Hemophilia Inhibitor PUP Study (HIPS) analyzed Factor VIII–specific antibodies in previously untreated infants with severe...
Conference Coverage
Cancer vaccine fails in CRC but trial yields lessons
SAN FRANCISCO – Tecemotide did not improve recurrence-free or overall survival relative to placebo when given after R0/R1 resection of liver-only...
Conference Coverage
Novel bispecific CAR shows promise in B-cell malignancies
SAN DIEGO – This is the first in-human study of a bispecific loop CAR in the United States.
Conference Coverage
Uninterrupted ibrutinib with CAR T could improve CLL outcomes
SAN DIEGO – Ibrutinib treatment before and after CAR T-cell therapy in CLL patients may decrease the risk of severe cytokine release syndrome.
Conference Coverage
Dual BRAF, MEK inhibition proves highly active in biliary tract cancer
SAN FRANCISCO – Patients with BRAF V600E–mutated biliary tract cancer in a basket trial had a response rate of 42% when given the combination of...
News
Combo treatment may improve quality of life in CTCL
LA JOLLA, CALIF. – In a small study, patients experienced relief from pruritus after just one cycle of treatment with brentuximab vedotin plus...